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background:  Early initiation of statin therapy during acute phase of ST-elevation myocardial infarction (STEMI) has been considered controversial 
particularly in patients with low plasma levels of low-density lipoprotein cholesterol (LDL-C). In this context we aimed to evaluate the impact of early 
use of statin after STEMI in the long-term incidence of cardiovascular events inpatients with LDL-C<100mg/dL.
methods: 530 consecutive STEMI patients from the prospective cohort Brazilian Heart Study were followed for mean 280±130days (median=365). 
Survival-free of cardiovascular events (sudden cardiac death and STEMI [MACE] with or without unstable angina with hospitalization [UA]) was 
analyzed by Cox regressions adjusted for age, gender, smoking, peak CK-MB and prior diagnosis of MI, diabetes, hypertension or use of statins. All 
patients treated by statin initiated the drug in the first 24-h of STEMI symptoms onset. Patients were divided into four groups according to the dose 
of statin during the first 7-days: no statin (NS;n=126), simvastatin 20mg (S20;n=130), 40mg (S40;n=151) and 80mg (S80;n=123). After discharge, 
all patients were treated by simvastatin, plus ezetimibe when necessary, to maintain during follow-up LDL-C<70mg/dL.
results: Patients in the S80 group experienced significantly less cardiovascular events when compared to NS group (HR for MACE of 0.27[0.09-
0.81],p=0.020; and HR for MACE+UA of 0.39[0.17-0.89], p=0.026). However, the same benefit was not evident among S20 and S40 groups, 
compared to NS group. When considering only patients with admission LDL-C<100mg/dL (n=160), although those who were treated with different 
statin doses tended to present reduced incidence of MACE, only S40 (n=44) and S80 (n=33) showed significant less MACE+UA (HR of 0.27[0.07-
0.99], p=0.048; and HR of 0.14[0.03-0.75], p=0.022, respectively) and only S80 had lower incidence of MACE (HR of 0.09[0.01-0.78], p=0.028) 
when compared to NS group.
Conclusions: The present findings suggest that the use of high-dose simvastatin during hospitalization after STEMI increases event-free survival 
and decreases the incidence of cardiovascular events, even in patients with admission LDL-C<100mg/dL.
